Isoniazid News and Research

RSS

Trial reveals value of tuberculosis chemoprophylaxis in HIV-infected people

Long-term follow-up in the ANRS TEMPRANO trial confirms that tuberculosis chemoprophylaxis in HIV-infected people is more than ever relevant in resource-limited countries.

10 Oct 2017

TB germs' metabolic 'escape pathways' may be neutralized by new drugs to shorten duration of therapy

New research suggests the bacteria that cause tuberculosis alter their metabolism to combat exposure to antimicrobials, and that these metabolic "escape pathways" might be neutralized by new drugs to shorten the troublesome duration of therapy.

31 May 2017

Directly observed therapy linked to decrease in mortality among MDR TB patients

Directly observed therapy (DOT) for multidrug-resistant tuberculosis (MDR TB) was associated with a 77 percent decrease in mortality in the United States, compared to self-administered therapy from 1993 to 2013, according to new research presented at the ATS 2017 International Conference.

22 May 2017

Report: Global increase in drug-resistant TB threatens to ruin efforts to eradicate the disease

The rise of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB) threatens to derail decades of progress in controlling the disease, according to a new report in The Lancet Respiratory Medicine published on World TB day (24th March).

25 Mar 2017

TB Alliance urges WHO to add Mycobacterium tuberculosis to list of drug-resistant bacteria

TB Alliance and the broader TB community urge that the World Health Organization (WHO) add Mycobacterium tuberculosis to the critical group within the list of drug-resistant bacteria identified as urgent priorities for research and development.

3 Mar 2017

Novel computer tool predicts impact of short-course treatment regimen against MDR-TB

Johns Hopkins researchers have developed a computer simulation that helps predict under which circumstances a new short-course treatment regimen for drug-resistant tuberculosis could substantially reduce the global incidence and spread of the disease.

16 Dec 2016

Botanical supplements may reduce effectiveness of common anti-tuberculosis drug, study finds

Botanical supplements are used by people around the world to treat a wide range of physical and mental ailments. Some of these botanical supplements have high levels of antioxidants, which may have some positive health effects for certain conditions.

12 Oct 2016

New ultra-fast molecular method can help detect mycobacterial pathogens in the lungs

What used to take several weeks is now possible in two days: Thanks to new molecular-based methods, mycobacterial pathogens that cause pulmonary infections or tuberculosis can now be detected much more quickly.

24 Jun 2016

Cochrane review explores FDCs versus single-drug formulations for treatment of pulmonary TB

A research team from Spain has prepared a Cochrane systematic review that explores the efficacy, safety, and adherence to fixed-dose combinations (FDCs) of drugs versus single-drug formulations to treat people who are newly diagnosed with tuberculosis (TB).

23 May 2016

Novel rapid diagnostic test and shorter treatment with better outcomes may benefit MDR-TB patients

New WHO recommendations aim to speed up detection and improve treatment outcomes for multidrug resistant tuberculosis (MDR-TB) through use of a novel rapid diagnostic test and a shorter, cheaper treatment regimen.

12 May 2016

New drug regimens could significantly improve treatment for tuberculosis

Researchers from UCLA and Shanghai Jiao Tong University have made an important step toward a substantially faster and more effective treatment for tuberculosis, which infects some 10 million people and causes 1.5 million deaths each year.

29 Mar 2016

Simple TB screening and isoniazid can be effective for HIV patients at risk for TB

The number one killer of HIV patients in resource-limited areas, including parts of Africa and India, is tuberculosis (TB), underscoring the need for optimal treatments and effective strategies to address this deadly co-infection. But TB is harder to detect in HIV-infected patients and diagnostic test results take time, so many healthcare providers prescribe multi-drug TB treatments as a precaution.

20 Mar 2016

Clinical study finds no added benefit of using four TB drugs to save people with advanced HIV/AIDS

In a report on the so-called REMEMBER (Reducing Early Mortality and Early Morbidity by Empiric Tuberculosis Treatment) study -- a 10-nation, randomized clinical trial of adult outpatients -- investigators concluded that there was no added benefit of using four drugs for TB over just using one drug, isoniazid, to save lives in people with advanced HIV/AIDS.

18 Mar 2016

Researchers document accuracy of new tests for rapid diagnosis of drug-resistant forms of TB

Researchers at University of California, San Diego School of Medicine have documented the accuracy of three new tests for more rapidly diagnosing drug-resistant forms of tuberculosis (TB), which are much harder and more expensive to treat and which, experts say, represent a major threat to global public health.

4 Sep 2015

New TB-Profiler tool to find appropriate drugs for TB patients may improve likelihood of cure

Finding out what drugs can be used to treat a patient with tuberculosis (TB) can be sped up by days or weeks, thanks to a new free online tool. The new TB-Profiler tool, developed by a team of scientists led by Dr Taane Clark at the London School of Hygiene & Tropical Medicine, analyses and interprets genome sequence data to predict resistance to 11 drugs used for the treatment of TB.

29 May 2015

Weill Cornell receives NIH grant to study TB-causing bacteria

In an effort to stop tuberculosis (TB) from becoming progressively less treatable worldwide, the National Institutes of Health has awarded Weill Cornell Medical College more than $6.2 million in first-year funding to support a research collaboration among six institutions in close alliance with voluntary pharmaceutical partners.

19 Feb 2015

FDA approves RYTARY for Parkinson's disease treatment

Impax Pharmaceuticals, a division of Impax Laboratories, Inc., today announced that the U.S. Food and Drug Administration approved RYTARY, an extended-release oral capsule formulation of carbidopa-levodopa, for the treatment of Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication and / or manganese intoxication.

8 Jan 2015

Eating food just before taking TB drug could reduce effectiveness of medicine

The timing of food intake in the early phase of TB treatment could have a negative impact on the effectiveness of TB treatment.

8 Sep 2014

Tuberculosis in children: an interview with Dr Peter Dodd, University of Sheffield

It was recently announced that new estimates indicated over 650,000 children develop tuberculosis (TB) every year in the 22 countries with a high burden of the disease (HBCs). Which countries are these and why are so many children developing TB in these areas?

29 Jul 2014

Over 650 000 children develop tuberculosis every year in the 22 HBCs according to new estimates

New estimates indicate that over 650 000 children develop tuberculosis (TB) every year in the 22 countries with a high burden of the disease (HBCs)*—almost 25% higher than the total number of new cases worldwide estimated by WHO in 2012 (530 000)**. The research, published in The Lancet Global Health, also suggests that about 15 million children are exposed to TB every year, and roughly 53 million are living with latent TB infection, which can progress to infectious active TB at any time.

9 Jul 2014